Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Dragonfleye takes flight raising $37.5 million in private placement offerings

Closely held Dragonfleye Therapeutics has announced that it completed two non-brokered private placements of common shares during 2026, raising aggregate gross proceeds of $37.5 million. Participants included healthcare...

October 26, 2026

Developments

TuHURA reveals initial data from study of adjunct therapy to Keytruda in MCC

TuHURA Biosciences (NASDAQ: HURA) announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment of metastatic Merkel Cell Carcinoma...

October 26, 2026

Developments

MacroGenics presents positive interim Phase 2 results for lorigerlimab at ESMO

MacroGenics (NASDAQ: MGNX) has announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, in patients with advanced clear cell...

October 26, 2026

Developments

Pasithea reports updated Phase 1 data for PAS-004 in solid tumors

Pasithea Therapeutics (NASDAQ: KTTA) has announced updated safety, tolerability, and preliminary efficacy data from its ongoing Phase 1 dose-escalation study of PAS-004 monotherapy in a heavily pre-treated population of...

October 23, 2026

Developments

Zentalis presents median OS data in ovarian cancer at ESMO 2026

Zentalis Pharmaceuticals (NASDAQ: ZNTL) presented results today from an interim analysis of the DENALI Part 1b study as of a May 22, 2026, data cutoff, including the first overall survival (OS) analysis for azenosertib...

October 23, 2026

Developments

Emmy-Award Winning TV host Montel Williams to join Profound’s next ‘Let’s Huddle’ webinar; company confirms first TULSA-PRO install at a VA facility

Profound Medical (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let’s Huddle...

October 22, 2026

Developments

PharmaJet achieves significant milestone with 25M intradermal injections delivered for polio eradication

Closely held PharmaJet has announced that their WHO-prequalified Tropis ID Needle-free Injection System has been used to deliver more than 25 million needle-free injections in support of polio eradication. According to...

October 22, 2026

Developments

Cognition and FDA align on Phase 3 study of zervimesine in DLB

Cognition Therapeutics (NASDAQ: CGTX) has announced alignment with the FDA on key elements of a Phase 3 study of either 100 mg of oral zervimesine or placebo for nine months in mild-to-moderate dementia with Lewy bodies...

October 22, 2026

Developments

BlossomHill, Foundation Medicine to develop first CDx for BH-30643 in EGFR C797S-mutated NSCLC

BlossomHill Therapeutics (NASDAQ: BLSM) has announced a collaboration with Foundation Medicine, a wholly owned subsidiary of Roche (SIX: RO, ROP; OTCQX: RHHBY), to develop the first companion diagnostic assay (CDx) for...

October 22, 2026

Developments

Lexaria reaches full enrollment in study evaluating oral DHT-sema against Wegovy

Lexaria Bioscience (NASDAQ: LEXX) has announced that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide (DHT-sema)...

October 21, 2026

Developments

INmune submits pre-MAA to MHRA for Ebstrocel in RDEB

INmune Bio (NASDAQ: INMB) has announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel...

October 21, 2026

Developments

Valion’s interim CEO Dean Zikria unveils 30-day agenda to advance pipeline and maximize shareholder value

Valion Bio (NASDAQ: VBIO) has shared the initial findings and priorities from Dean Zikria’s first 30 days as interim chief executive officer (CEO). Mr. Zikria’s strategic review has set a focused agenda built on three...

October 21, 2026

Developments

Findings identify Propanc’s PRP as potential strategy to reprogram chemo-resistant pancreatic cancer

Propanc Biopharma (NASDAQ: PPCB) has announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, that has identified the company’s...

October 16, 2026

Developments

PharmaJet highlights vaccine development opportunities and real-world impact with needle-free delivery at World Vaccine Congress Europe

Closely held PharmaJet has announced its participation in a pre-conference panel at the World Vaccine Conference Europe on October 19, 2026, at 14:15. Entitled From Non-Inferiority to Impact: Accelerating Adoption of...

October 16, 2026

Developments

TIME honors Perimeter’s Claire OCT with special mention on 2026 Best Innovations list

TIME’s Best Innovations of 2026 includes a special mention of Perimeter Medical Imaging AI’s (TSX-V: PINK; OTCQX: PYNKF) Claire OCT System. Claire is the only FDA-approved imaging...

October 15, 2026

Developments

Valion’s next-gen NMR partnership with LarmorBio delivers initial feasibility milestone

Valion Bio (NASDAQ: VBIO) and closely held LarmorBio today announced that Velocity Bioworks, Valion’s wholly owned biologics contract development and manufacturing organization (CDMO) subsidiary, has successfully...

October 15, 2026

Developments

FDA clears Edesa’s IND for Phase 2 vitiligo study

Edesa Biotech (NASDAQ: EDSA) has announced that the FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment...

October 15, 2026

Developments

Xenetic and PeriNess report first patient dosed in investigator-led study at TASMC

Xenetic Biosciences (NASDAQ: XBIO) has announced that its collaboration partner, closely held PeriNess, has informed the company that the first patient has been dosed in an investigator-initiated clinical study...

October 15, 2026

Developments

Valion’s Velocity Bioworks capitalizes on domestic CDMO surge amid Section 232 tariffs

Valion Bio (NASDAQ: VBIO) has highlighted the capabilities of its wholly owned contract development and manufacturing organization (CDMO), Velocity Bioworks. Velocity is part of Valion’s own domestic biologics...

October 14, 2026

Developments

Profound’s TULSA abstracts at the 15th iMRI Symposium strengthen real-world evidence, clinical differentiation, and platform expansion opportunity

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that five abstracts presented at the 15th Interventional MRI (iMRI) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real...

October 14, 2026

Developments

JWC publishes trial results for Organogenesis’ PuraPly AM in DFUs

Organogenesis Holdings (NASDAQ: ORGO) has announced the publication of peer-reviewed trial results in the Journal of Wound Care (JWC) showing the clinical benefit of PuraPly AM for hard-to-treat diabetic foot ulcers...

October 13, 2026

Developments

USPTO grants Cognition patent for zervimesine through 2045

Cognition Therapeutics (NASDAQ: CGTX) has announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), providing...

October 13, 2026

Subscribe